Brokerages Set Simulations Plus, Inc. (NASDAQ:SLP) Target Price at $50.00

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have received an average rating of “Buy” from the six research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.25.

SLP has been the subject of several research reports. Wall Street Zen raised Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Tuesday, June 3rd. Finally, KeyCorp raised their price target on Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th.

Simulations Plus Stock Down 24.2%

SLP stock opened at $20.05 on Friday. The company has a 50-day simple moving average of $30.84 and a 200 day simple moving average of $30.31. The company has a market capitalization of $403.23 million, a P/E ratio of 50.13 and a beta of 0.97. Simulations Plus has a fifty-two week low of $19.26 and a fifty-two week high of $50.11.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.06. The business had revenue of $22.43 million during the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. Equities analysts anticipate that Simulations Plus will post 1.09 EPS for the current year.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the completion of the sale, the director now owns 3,344,157 shares in the company, valued at $112,062,701.07. The trade was a 0.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 19.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Simulations Plus

Large investors have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in shares of Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock worth $34,000 after buying an additional 427 shares during the period. Fifth Third Bancorp lifted its stake in Simulations Plus by 33.8% in the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after acquiring an additional 375 shares during the last quarter. Johnson Financial Group Inc. bought a new position in Simulations Plus during the fourth quarter worth about $39,000. Tower Research Capital LLC TRC raised its stake in Simulations Plus by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after acquiring an additional 764 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Simulations Plus by 502.9% in the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after purchasing an additional 2,243 shares during the period. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.